Health Economics›Follicular lymphoma›Relapsed or refractory non-randomized or retrospective data

Relapsed or refractory non-randomized or retrospective data

Follicular lymphoma · 22 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Fludarabine and Rituximab (FR) Variant #06	—	R 117 749	28d	—	—	—	—	—
Ibrutinib monotherapy Variant #01	—	R 80 133	28d	~44.1 mo	—	~48	~R 3 846 377 PFS proxy · indirect	15
BVR Variant #02	—	R 69 654	35d	—	—	—	—	—
R-FND Variant #02	—	R 46 106	28d	—	—	—	—	—
R-DexaBEAM Variant #01 Partial	—	R 25 792	28d	—	—	—	—	—
VR-CP Variant #01	—	R 14 681	21d	—	—	—	—	—
R-CVP Variant #01	—	R 12 182	21d	—	—	—	—	1
Vorinostat and Rituximab Variant #01 Partial	—	R 11 796	21d	—	—	—	—	—
R-INO Variant #01 Partial	—	R 11 796	28d	—	~9.5 mo	—	—	1
Bortezomib monotherapy Variant #14	—	R 8 539	35d	~30.3 mo	—	~27	~R 230 565 PFS proxy · indirect	5
Epcoritamab monotherapy N/A - secondary systemic drug	—	R 169	—	—	—	—	—	—
PEP-C Variant #01 Partial	—	R 110	—	—	—	—	—	—
Temsirolimus monotherapy N/A - secondary systemic drug	—	R 0	28d	~4.8 mo	~17.2 mo	~6	~R 1 PFS proxy · indirect	3
Axicabtagene ciloleucel monotherapy N/A - secondary systemic drug	—	R 0	—	—	—	—	—	1
Duvelisib monotherapy Variant #01 Partial	—	—	28d	~13.3 mo	—	~15	—	1
Mosunetuzumab monotherapy Variant #01 Partial	—	—	21d	—	—	—	—	—
Vorinostat monotherapy Variant #01 Partial	—	—	28d	~3.1 mo	—	~4	—	1
Inotuzumab ozogamicin monotherapy Variant #01 Partial	—	—	28d	—	~7.7 mo	—	—	1
Tisagenlecleucel monotherapy Variant #01 Partial	—	—	—	—	—	—	—	—
Tazemetostat monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—
Copanlisib monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—
Lisocabtagene maraleucel monotherapy Variant #01 Partial	—	—	—	—	—	—	—	—

22 of 22 regimens shown